RELAY THERAPEUTICS INC (RLAY) — insider trading
Health Care · NASDAQ
RELAY THERAPEUTICS INC (RLAY) has 43 reported SEC Form 4 insider transactions in our data, including 26 open-market sales among the most recent 43 (latest 2026-10-07).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Patel Sanjiv | Director, Officer (President and CEO) | Open-market sale | 48,199 | $18.10 | $872.4K | Form 4 |
| 2026-10-06 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 206 | $19.26 | $4.0K | Form 4 |
| 2026-10-06 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,511 | $18.58 | $325.4K | Form 4 |
| 2026-09-08 | Patel Sanjiv | Director, Officer (President and CEO) | Open-market sale | 48,199 | $18.94 | $912.9K | Form 4 |
| 2026-09-08 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,717 | $18.94 | $335.6K | Form 4 |
| 2026-09-08 | Bergstrom Donald A | Officer (President, R&D) | Open-market sale | 8,530 | $18.97 | $161.8K | Form 4 |
| 2026-08-26 | Rahmer Peter | Officer (See remarks) | Open-market sale | 4,508 | $20.03 | $90.3K | Form 4 |
| 2026-08-25 | SVF Pauling (Cayman) Ltd; SOFTBANK VISION FUND (AIV M2) L.P.; SB INVESTMENT ADVISERS (UK) LTD | 10% owner | Open-market sale | 6,000,000 | $19.40 | $116.40M | Form 4 |
| 2026-08-17 | Patel Sanjiv | Director, Officer (President and CEO) | Open-market sale | 48,199 | $20.33 | $979.9K | Form 4 |
| 2026-08-14 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,717 | $19.74 | $349.7K | Form 4 |
| 2026-07-28 | Bergstrom Donald A | Officer (President, R&D) | Open-market sale | 2,237 | $18.61 | $41.6K | Form 4 |
| 2026-07-28 | Rahmer Peter | Officer (See remarks) | Open-market sale | 748 | $18.61 | $13.9K | Form 4 |
| 2026-07-28 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 1,459 | $18.61 | $27.2K | Form 4 |
| 2026-07-07 | Patel Sanjiv | Director, Officer (President and CEO) | Open-market sale | 48,199 | $19.58 | $943.7K | Form 4 |
| 2026-07-06 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,717 | $18.69 | $331.1K | Form 4 |
| 2026-07-06 | Bergstrom Donald A | Officer (President, R&D) | Open-market sale | 8,660 | $18.71 | $162.0K | Form 4 |
| 2026-06-30 | Patel Sanjiv | Director, Officer (President and CEO) | Grant / award / vesting | 3,056 | $6.95 | $21.2K | Form 4 |
| 2026-06-30 | Rahmer Peter | Officer (See remarks) | Grant / award / vesting | 3,056 | $6.95 | $21.2K | Form 4 |
| 2026-06-30 | Rahmer Peter | Officer (See remarks) | Open-market sale | 50,000 | $19.09 | $954.5K | Form 4 |
| 2026-06-22 | Bergstrom Donald A | Officer (President, R&D) | Option exercise / conversion (derivative) | 93,456 | — | $0 | Form 4 |
| 2026-06-22 | Bergstrom Donald A | Officer (President, R&D) | Open-market sale | 93,456 | $16.94 | $1.58M | Form 4 |
| 2026-06-22 | Bergstrom Donald A | Officer (President, R&D) | Option exercise / conversion | 93,456 | $4.12 | $385.0K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 51,560 | — | $0 | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 61,563 | — | $0 | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 56,323 | — | $0 | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 51,560 | $16.97 | $875.0K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion | 51,560 | $4.45 | $229.4K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 61,563 | $16.97 | $1.04M | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion | 61,563 | $5.22 | $321.4K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 56,323 | $16.97 | $955.8K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Option exercise / conversion | 56,323 | $5.04 | $283.9K | Form 4 |
| 2026-06-22 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,717 | $17.01 | $301.4K | Form 4 |
| 2026-06-09 | Murcko Mark | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | COATS LONNEL | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | INGRAM DOUGLAS S | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | Borisy Alexis | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | HILL LINDA A | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | Dable Habib J | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-06-09 | Mazumdar Claire | Director | Grant / award / vesting (derivative) | 32,947 | — | $0 | Form 4 |
| 2026-05-14 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 17,717 | $12.86 | $227.8K | Form 4 |
| 2026-04-28 | Bergstrom Donald A | Officer (President, R&D) | Open-market sale | 1,490 | $14.79 | $22.0K | Form 4 |
| 2026-04-28 | Rahmer Peter | Officer (See remarks) | Open-market sale | 753 | $14.79 | $11.1K | Form 4 |
| 2026-04-28 | Catinazzo Thomas | Officer (Chief Financial Officer) | Open-market sale | 972 | $14.79 | $14.4K | Form 4 |
Ask the chat about RLAY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: RELAY THERAPEUTICS INC (RLAY).
Last updated 2026-10-07 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.